Han Kun Law Offices

Legal Services | Mainland China, China
tel: (86 10) 8525 5500
9F, Office Tower C1, Oriental Plaza, 1 East Chang An Avenue | Beijing | Mainland China | 100738 | China

Main Contacts

Yan Wang

|
Partner

Overview

Han Kun is a leading full-service law firm in China. Over the years, Han Kun has been widely recognized as a leader in complex cross-border and domestic transactions and compliance matters.

Our main practice areas include private equity, mergers and acquisitions, international and domestic capital markets, investment funds, asset management, compliance, banking and finance, aviation finance, foreign direct investment, antitrust/competition, data protection, private client/wealth management, intellectual property, bankruptcy and restructuring and dispute resolution.

We have more than 900 professionals located in Beijing, Shanghai, Shenzhen, Hangzhou, Wuhan, Haikou, Hong Kong, Singapore, New York, Silicon Valley and London.

All our lawyers are graduates of top universities and have extensive experience in complex cross-border transactions and dispute resolution as counsel to both Chinese and foreign clients.

Our working languages include Chinese, English, Japanese, Korean and German.

Year this Office was Established: 2004
Lawyers Worldwide: 900

Areas of Practice

Professionals

Partners

Yijun  Chao

Yijun Chao

Partner
Dafei  Chen

Dafei Chen

Partner
Yang  Chen

Yang Chen

Partner
Xiaoming  Deng

Xiaoming Deng

Partners
Min  Duan

Min Duan

Partner
Rong  Fang

Rong Fang

Partner
Lin  Gui

Lin Gui

Partner
Yang  Han

Yang Han

Partner
Chunyan  He

Chunyan He

Partner
Jun  He

Jun He

Partner
Rui  Huang

Rui Huang

Partner
Dongni  Jiang

Dongni Jiang

Partners
Wenyu  Jin

Wenyu Jin

Partner
Tao  Lan

Tao Lan

Partner
Xun  Li

Xun Li

Partner
Jing  Li

Jing Li

Partner
SHENG  LI

SHENG LI

Partner
Xiaoming  Li

Xiaoming Li

Partner
Shijia  LI

Shijia LI

Partner
Baofu  Li

Baofu Li

Partner
Ying  Li

Ying Li

Partners
Yipu  Li

Yipu Li

Partners
Yixin  Lin

Yixin Lin

Partner
Ruina  Liu

Ruina Liu

Partner
Jiaxin  LIU

Jiaxin LIU

Partner
Jing  Liu

Jing Liu

Partner
Long  Liu

Long Liu

Partner
Xiayi  Liu

Xiayi Liu

Partner
Lifeng  Lu

Lifeng Lu

Partner
Zaiguang  LU

Zaiguang LU

Partner
Rui  Luo

Rui Luo

Partner
Shaolin  Luo

Shaolin Luo

Partner
Chen  Ma

Chen Ma

Partner
Xiu  Pei

Xiu Pei

Partner
Lu  Ran

Lu Ran

Partner
Da  Shi

Da Shi

Partners
Haining  Song

Haining Song

Partner
Hua  Tu

Hua Tu

Partner
Xikang  Wang

Xikang Wang

Partner
Shu  WANG

Shu WANG

Partner
Jin  Wang

Jin Wang

Partner
Xiaowei  WEI

Xiaowei WEI

Partner
Lili  WU

Lili WU

Partner
Kaiying  WU

Kaiying WU

Partner
Ying  YANG

Ying YANG

Partner
Yang  You

Yang You

Partner
Lan  Yu

Lan Yu

Partner
Shiye  Yuan

Shiye Yuan

Partner
Liming  Yuan

Liming Yuan

Partner
Jian  Zhang

Jian Zhang

Partner
Yaxing  Zhang

Yaxing Zhang

Partner
Tao  ZHANG

Tao ZHANG

Partner
Zhao  Zhang

Zhao Zhang

Partner
Pei  Zhao

Pei Zhao

Partner
Bin  ZHI

Bin ZHI

Partner
Lin  ZHOU

Lin ZHOU

Partner
Jun  ZHU

Jun ZHU

Partner

Associates

Yi  Bian

Yi Bian

Associate
Yuanyuan  Chu

Yuanyuan Chu

Associate
Ying  Huang

Ying Huang

Associates
Qiongxing  WANG

Qiongxing WANG

Associate

Of Counsel

Han  Chen

Han Chen

Counsel
Junfeng  Cui

Junfeng Cui

Of Counsel
Jie (Jessie)  Dong

Jie (Jessie) Dong

Of Counsel
Xiao  Guo

Xiao Guo

Of Counsel
Zhehao  Li

Zhehao Li

Of Counsel
Qian  Li

Qian Li

Of Counsel
Jingbo  Luo

Jingbo Luo

Of Counsel
Bing  San

Bing San

Of Counsel
Yikai  Wang

Yikai Wang

Of Counsel
Zhenyu  Wang

Zhenyu Wang

Of Counsel
Yichen  Wu

Yichen Wu

Of Counsel
Ying  Zeng

Ying Zeng

Of Counsel
Qi  Zhang

Qi Zhang

Of Counsel
Xinfeng  Zhang

Xinfeng Zhang

Of Counsel
Yuxuan  Zhang

Yuxuan Zhang

Of Counsel
Yunzhi  Zhao

Yunzhi Zhao

Of Counsel

Other

Xiaomeng  Dong

Xiaomeng Dong

Manager of trademark application department
Michael  Jiawei He

Michael Jiawei He

Chief Marketing Officer
Chengrong (Paul)  Li

Chengrong (Paul) Li

Partner & Solicitor
Sara  Shao

Sara Shao

Business Development Manager
Tongyi  Wang

Tongyi Wang

Marketing
Jenny  Xu

Jenny Xu

Marketing

Articles

Domestic Remedies for Overseas Securities Fraud: Insights from the Extraterritorial Application of the PRC Securities Law

In 2026, the Beijing Financial Court and the High People's Court of Beijing Municipality("Beijing High People's Court")ruled that Chinese mainland courts had jurisdiction over securities fraud involving a Cayman Islands company listed on the Hong Kong Stock Exchange (HKEX). This landmark decision sets a precedent as the first instance in which judicial authorities in Chinese mainland applied the Securities Law of the PRC (the "Securities Law") extraterritorially. The decision is recognized as a "typical case" and has been included in theReport on the Work of the Supreme People's Court (2026)[1]...

China's HGR Draft Rules Signal Regulatory Easing: Key Takeaways from the Implementing Rules for the Administrative Regulation on Human Genetic Resources (Draft for Comments)

On May 8, 2026, the National Health Commission ("NHC") released theImplementing Rules for the Administrative Regulation on Human Genetic Resources (Draft for Comments)("Draft for Comments"), proposing amendments to the currentImplementing Rules for the Administrative Regulation on Human Genetic Resources("Current Implementing Rules") formulated by the Ministry of Science and Technology ("MOST") in 2023 (for our interpretation of the Current Implementing Rules, please see our previous article:Han Kun Perspective First Release: Key Takeaways from the Implementing Rules for the Administrative Regulation on Human Genetic Resources), and is soliciting public comments...

VIEW ALL Han Kun Articles

Press releases

Han Kun Advises Everest Medicines in Acquiring an Exclusive License with Vcare PharmaTech for Sumecigrel, a P2Y12 receptor antagonist, in Asia-Pacific Markets

On June 9, 2026, Everest Medicines (HKEX: 1952) announced that it had entered into an agreement with Jiangsu Vcare PharmaTech Co., Ltd. ("Vcare PharmaTech"), under which Everest Medicines obtained the exclusive rights to develop, register and commercialize Sumecigrel (formerly known as Vicagrel), a P2Y12 receptor antagonist, in multiple countries and regions across Asia-Pacific, including Southeast Asia, South Korea, Australia, Hong Kong Special Administrative Region, Macau Special Administrative Region and Taiwan region, China...

Han Kun again recognized in MIP's IP STARS rankings

Managing Intellectual Property (MIP), a world-renowned IP publication, has recently announced its 2026 global IP STARS rankings.  Han Kun was again recognized in the China domestic firm categories of "IP transactions (Tier 1)", "Patent disputes", "Trademark disputes", "Patent prosecution", and "Copyright", owing to the firm's competitive IP division and exceptional service capabilities.  This is the sixth consecutive year for Han Kun to appear in the rankings, which reflects MIP's affirmation of the firm's comprehensive strength and influence.Besides these firm-level accolades, Han Kun partners Lili Wu and Yan Wang were recognized as "IP Stars" again...

VIEW ALL Han Kun Press
dots